| Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study) (NCT07744698) | Anhui Provincial Cancer Hospital | 2026-07-24 |
| Becotatug Vedotin Combined With Pucotenlimab ± Radiotherapy as First-Line Treatment for Driver-Gene-Negative, EGFR-Expression-Positive Advanced Non-Small Cell Lung Cancer (NCT07627321) | Anhui Provincial Cancer Hospital | 2026-07-15 |
| Super-Resolution Ultrasound Imaging for Assessing Response to Neoadjuvant Chemotherapy in Breast Cancer (NCT07623226) | Anhui Provincial Cancer Hospital | 2026-06-01 |
| A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Therapy for Advanced Gastric Cancer (NCT07371871) | Anhui Provincial Cancer Hospital | 2026-01-08 |
| Noninvasive Real-Time Arterial Waveform Monitoring for Cardiovascular Disease Assessment (NCT07350629) | Anhui Provincial Cancer Hospital | 2025-12-26 |
| An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer (NCT07299890) | Anhui Provincial Cancer Hospital | 2025-12-20 |
| QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC (NCT07330596) | Anhui Provincial Cancer Hospital | 2025-10-30 |
| A Phase II Exploratory Study of Iparomlimab and Tuvonralimab Combined With Chemotherapy in Neoadjuvant Treatment of HR+/HER2- Breast Cancer Patients (NCT07197697) | Anhui Provincial Cancer Hospital | 2025-10-10 |
| SHR-1811 Combined With Carboplatin in the Treatment of Advanced Breast Cancer With HER2 Expression (NCT07047443) | Anhui Provincial Cancer Hospital | 2025-08-01 |
| An Exploratory Study on NK Cell-assisted Prevention of Bone Marrow Suppression During Chemotherapy for Ovarian Cancer (NCT07096583) | Anhui Provincial Cancer Hospital | 2025-07-07 |
| Sintilimab Plus Apatinib and SOX as First-line Treatment in Patients With AFP Gastric or Gastroesophageal Junction Adenocarcinoma (NCT06973330) | Anhui Provincial Cancer Hospital | 2025-07-01 |
| PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy (NCT07014215) | Anhui Provincial Cancer Hospital | 2025-06-01 |
| Super-Resolution Ultrasound Microvascular Mapping for Non-Invasive Breast Cancer Molecular Subtyping: A Validated Nomogram (NCT07581054) | Anhui Provincial Cancer Hospital | 2025-05-07 |
| Sintilimab Plus Bevacizumab and Chemotherapy in MSS/pMMR Colorectal With no Liver Metastasis (NCT06973343) | Anhui Provincial Cancer Hospital | 2025-05-01 |
| METR-NK Cells in Combination With Anti-angiogenic Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer (NCT06884345) | Anhui Provincial Cancer Hospital | 2025-03-13 |
| Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC (NCT06838208) | Anhui Provincial Cancer Hospital | 2025-02-25 |
| Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC (NCT06714708) | Anhui Provincial Cancer Hospital | 2024-11-20 |
| An Exploratory Clinical Study of Statins for Improving Chemotherapy and Maintenance in Patients With Ovarian Cancer (NCT06468254) | Anhui Provincial Cancer Hospital | 2024-06-30 |
| Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer (NCT06437353) | Anhui Provincial Cancer Hospital | 2024-05-25 |
| Safety and Efficacy of Intraperitoneal Injection of METR-NK Cells as Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer (NCT06395844) | Anhui Provincial Cancer Hospital | 2024-05-01 |
| A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer (NCT05414630) | Anhui Provincial Cancer Hospital | 2022-06-01 |
| Avatrombopag on the Treatment of Thrombocytopenia Induced by Chemotherapy of Malignant Tumors (NCT04609891) | Anhui Provincial Cancer Hospital | 2020-05-26 |